Syncromune^® Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-in-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer

Syncromune® Inc. announced that the US FDA has cleared the investigational new drug (IND) application for SYNC-T SV-102, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.